Advertisement

Topics

Antibodies Corporate

09:06 EDT 18th October 2017 | BioPortfolio

Asklepios BioPharmaceutical, Inc.

AskBio is a private clinical-stage biotechnology company engaged in the development of novel, gene-transfer mediated therapies using a proprietary AAV-based vector technology platform. This technology is being used to deliver a broad range of therapeutics including therapeutic DNA, monoclonal antibodies, RNAi, and vaccines, among others. The company’s...

Immune Pharmaceuticals, Inc.

Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Our lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to ...

CBT Pharmaceuticals, Inc.

CBT Pharmaceuticals is a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer. The company is advancing a pipeline of four development-stage assets. CBT-101, is an oral c-MET inhibitor targeting the epithelial to mesenchymal transition (EMT) pa...

Synergys Biotherapeutics

Synergys is an early stage company developing multifunctional anti-vascularization antibody drugs targeting VEGF-alternative pathways. The Company’s most advanced product candidate, Anti-EGFR‐TAP (SYN001) was derived from its platform technology termed A‐TAP (Antibody-Targeted Anti-Vascularization Payload). SYN001 is currently in preclinical ...

Opsidio, LLC

Opsidio, LLC is a preclinical stage biopharmaceutical company developing monoclonal antibodies to treat fibrotic diseases. Opsidio is headquartered in Bryn Mawr, PA with additional facilities in Ann Arbor, MI. For further information, please contact Martin Phillips or Jim Jogerst, at info@opsidio.com

AbCellera Biologics, Inc.

AbCellera is a privately held company that develops next-generation monoclonal antibody therapies and provides enabling technologies to biotechnology and pharmaceutical partners. AbCellera’s lead technology is a proprietary single-cell antibody discovery and immune profiling platform that allows for high-throughput screening of natural immune repertoi...

Adello Biologics, LLC

Adello is a privately held, U.S.-based biotechnology company headquartered in Piscataway, NJ. The company's aim is to provide high-quality, affordable biosimilars to patients worldwide. Driven by a team of highly skilled industry veterans, Adello is advancing a pipeline of complex proteins and monoclonal antibodies with lead candidates in oncology and immu...

Unum Therapeutics Inc.

Unum Therapeutics uses its proprietary Antibody-Coupled T cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, which is designed to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in which proprietary, tumor-targeting antibodies are armed to improve their therapeut...

Grid Therapeutics, LLC

Grid Therapeutics is a biotech company based on the innovative platform for discovering and isolating human derived antibodies. Dr Edward F. Patz, Jr, is the co-founder and CEO of Grid, located in Durham, North Carolina. The lead antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. ...

Abreos Biosciences

Abreos Biosciences is focused on ligand binding assays for biologic and biosimilar drug development, activity validation, authentication, and precision dosing, as well as massively multiplexed biomarker assays. Abreos has already developed reagents for the detection of several drugs currently available on the market such as rituximab, obinutuzumab, trastuz...

Y-mAbs Therapeutics, Inc.

Dendreon

Dendreon Corporation (Nasdaq: DNDN) is a Seattle-based biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. Through innovative science and technology, we are striving to develop and commercialize products that address unmet medical need, improve surv...

EpimAb Biotherapeutics

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics...

ImmunoGen

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, TAPs are intended to deliver potent chemotherapy specifically to a tumor. Each TAP immunoconjugate comprises a small-molecule d...

SIWA Therapeutics

SIWA Therapeutics is a privately held biotechnology company based in Chicago. SIWA has shown that its monoclonal antibody, SIWA 318, targets and destroys senescent cells in animal models without observable side effects of treatment. Although senescent cells are causally implicated in a wide variety of diseases including neurodegenerative diseases, autoimmu...

Immunomedics, Inc.

Immunomedics (the “Company”) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled ...

Alexo Therapeutics

Alexo Therapeutics is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin....

CBT Pharmaceuticals

CBT Pharmaceuticals is a life sciences company developing innovative oncology therapeutics targeting the growth and proliferation of cancer cells. The company is advancing a pipeline of four development-stage assets including CBT-101, an oral c-Met inhibitor targeting the epithelial-mesenchymal transition (EMT) pathway in cancers and CBT-501, a novel human...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

Invenra, Inc.

Invenra is a pre-clinical stage bio-pharmaceutical company focused on discovering the next generation of best-in-class biologics, with an emphasis on monoclonal antibodies (mAbs), bispecific antibodies using their proprietary B-Body™ and TAIL™ platforms, empowered mAbs and their derivatives. Invenra’s proprietary technology combines state-of-the-ar...

Ossianix Inc.

Ossianix is a privately held research company based in Philadelphia, PA with research laboratories in Stevenage, UK. It develops novel biopharmaceuticals for a number of therapeutic areas including CNS. The company utilizes the versatile single domain shark VNAR scaffold to engineer unique differentiated products in a variety of formats including monospeci...

MorphoSys AG

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceu...

Arsanis, Inc.

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated wit...

SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, S.D. is an established, biopharmaceutical company that is leading the science and manufacturing of immunoglobulin therapies. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large scale platform to create fully human immunoglobulins. Th...

SynAffix

SynAffix is a protein engineering company located in Oss (the Netherlands), focused on the development of next-generation Antibody-Drug Conjugates (ADCs) for targeted cancer and other diseases. SynAffix’ proprietary site-specific bioconjugation technology (GlycoConnectTM) enables the attachment of a toxic drug to a glycoprotein of interest without requiring prior engineering of the protein...

Quick Search
Advertisement
 

review and buy Antibodies market research data and corporate reports here